New HIV Guidelines

vailable July 21 issue of JAMA (free, please read the full article from there).

Not sure I agree with all recommendations.  This is the curse of 'growing up' in medicine and therefore developing your own opinion.

I think it is too early to consider raltegravir (and maybe even darunavir) as first line therapies in treatment naive patients.  Especially with other options available.  The authors hint at this point but are not explicit enough for the audience of the guideline (in my humble opinion)

Likewise for starting with CD4 greater than 500.  Those patients should be enrolled in properly designed prospective studies (hence the CIII recommendation)